Key result
Minimally invasive mitral valve surgery demonstrated similar 30-day mortality (1% vs 3%, p=0.25) and 5-year survival compared to conventional sternotomy, while significantly reducing the need for transfusions and reoperation for bleeding.
Why the study?
Less-invasive approaches to mitral valve surgery are increasingly used, but whether minimally invasive surgery is superior to conventional median sternotomy remains uncertain.
Does minimally invasive mitral valve surgery improve short- and mid-term outcomes compared to conventional sternotomy in patients undergoing isolated mitral valve surgery?
Cohort (n=525)
No
Does minimally invasive mitral valve surgery improve short- and mid-term outcomes compared to conventional sternotomy in patients undergoing isolated mitral valve surgery?
Absolute Event Rate: 1% vs 3%
p-value: p=0.25
Minimally invasive mitral valve surgery via minithoracotomy is safe and provides comparable mid-term survival to conventional sternotomy, while significantly reducing the need for blood transfusions and reoperation for bleeding.
May reduce transfusions and reoperations without excess mortality; leaves open confirmation in randomized trials.
OBJECTIVES: Conventional mitral valve surgery through median sternotomy improves long-term survival with acceptable morbidity and mortality. However, less-invasive approaches to mitral valve surgery are now increasingly employed. Whether minimally invasive mitral valve surgery is superior to conventional surgery is uncertain. METHODS: A retrospective analysis of patients who underwent mitral valve surgery via minithoracotomy or median sternotomy between 2012 and 2018. A propensity score-matched analysis was generated to eliminate differences in relevant preoperative risk factors between the two groups. RESULTS: Data from 525 patients were evaluated, 189 underwent minithoracotomy and 336 underwent median sternotomy. The 30 day mortality was similar between the minithoracotomy and conventional surgery groups (1 and 3%, respectively; p = 0.25). No differences were seen in the incidence of stroke (p = 1.00), surgical site infections (p = 0.09), or myocardial infarction (p = 0.23), or in total hospital cost (p = 0.48). However, the minimally invasive approach was associated with fewer patients receiving transfusions (59% versus 76% in the conventional group; p = 0.001) or requiring reoperation for bleeding (3% versus 9%, respectively; p = 0.03). There were no significant differences in 5 year survival between the minithoracotomy and conventional surgery groups (93% versus 86%, respectively; p = 0.21) and freedom from mitral valve reoperation (95% versus 94%, respectively; p = 0.79). CONCLUSIONS: In patients undergoing mitral valve surgery, a minimally invasive approach is feasible, safe, and reproducible with excellent short-term outcomes; mid-term outcomes and efficacy were also seen to be comparable to conventional sternotomy.
No takes yet. Share an insight, caveat, or question.
Pojar et al. (2021) conducted a cohort in Mitral valve disease requiring surgery (n=525). Minimally invasive minithoracotomy vs. Conventional full median sternotomy was evaluated on 30-day mortality (p=0.25). Minimally invasive mitral valve surgery demonstrated similar 30-day mortality (1% vs 3%, p=0.25) and 5-year survival compared to conventional sternotomy, while significantly reducing the need for transfusions and reoperation for bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: